The burden of age-related macular degeneration: A value-based medicine analysis

Gary C. Brown, Melissa M. Brown, Sanjay Sharma, Joshua D. Stein, Zachary Roth, Joseph Campanella, George R. Beauchamp, Frederick L. Ferris, Richard L. Lindstrom, M. Edward Wilson, Elias I. Traboulsi, Douglas R. Anderson, Steven E. Feldon, J. Bronwyn Bateman, Travis A. Meredith

Research output: Contribution to journalArticle

82 Scopus citations

Abstract

Purpose: To assess the quality-of-life loss and the macroeconomic financial consequences associated with age-related macular degeneration (ARMD). Methods: Time tradeoff utility analysis was performed to assess the quality-of-life diminution caused by ARMD (both dry and neovascular) in cohorts consisting of (1) patients with ARMD, (2) ophthalmologists asked to assume they had various degrees of severity of ARMD, (3) healthcare providers asked to assume they had various degrees of severity of ARMD, and (4) participants from the general community asked to assume they had various degrees of severity of ARMD. ARMD was classified according to vision in the better-seeing eye as (1) mild: 20/20 to 20/40, (2) moderate: 20/50 to 20/100, (3) severe: ≤20/200, or (4) very severe: ≤20/800. Results: Mild ARMD caused a 17% decrement in the quality of life of the average patient, similar to that encountered with moderate cardiac angina or symptomatic human immunodeficiency virus syndrome. Moderate ARMD caused a 32% decrease in the average patient's quality of life, similar to that associated with severe cardiac angina or a fractured hip. Severe ARMD caused a 53% decrease in quality, more than that of dialysis, and very severe ARMD caused a 60% decrease in the average ARMD patient's quality of life, similar to that encountered with end-stage prostate cancer or a catastrophic stroke that leaves a person bedridden, incontinent, and requiring constant nursing care. Patients with varying degrees of severity of ARMD were found to have quality-of-life impairment ranging from 96% to 750% greater than that estimated by treating ophthalmologists for the same condition. An economic analysis based upon losses to the gross domestic product suggests that ARMD has approximately a $30 billion annual negative impact. The return on investment is therefore potentially high for both treatment with current ARMD therapies and the research costs invested in the development of new ARMD treatment modalities. Conclusions: ARMD is a major public health problem that has a devastating effect upon patients and marked adverse financial consequences for the economy.

Original languageEnglish (US)
Pages (from-to)173-186
Number of pages14
JournalTransactions of the American Ophthalmological Society
Volume103
StatePublished - Dec 1 2005

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'The burden of age-related macular degeneration: A value-based medicine analysis'. Together they form a unique fingerprint.

  • Cite this

    Brown, G. C., Brown, M. M., Sharma, S., Stein, J. D., Roth, Z., Campanella, J., Beauchamp, G. R., Ferris, F. L., Lindstrom, R. L., Wilson, M. E., Traboulsi, E. I., Anderson, D. R., Feldon, S. E., Bateman, J. B., & Meredith, T. A. (2005). The burden of age-related macular degeneration: A value-based medicine analysis. Transactions of the American Ophthalmological Society, 103, 173-186.